CHEST Physician
-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
-
Prevention of COPD exacerbations with an eosinophilic endotype
With the recent US approval of the IL-5-directed monoclonal antibody mepolizumab as an add-on therapy for patients with COPD, the era of COPD biologics is undeniably here.
-
Moderate to severe OSA increases risk of severe COVID-19
According to critical care specialist Lina Miyakawa, MD, FCCP, the findings are a reminder that OSA “is not just a sleep disorder but a systemic condition with meaningful public health implications.”
-
Shock resuscitation: Making the first 30 minutes count
Physician-educators share their approach to teaching shock recognition and management core skills to residents at the bedside.
-
Optimizing lung transplant care
In the evolving landscape of transplant medicine, APPs are proving to be indispensable through their clinical expertise, consistency, and adaptability across care settings.
-
Beyond the pump: Clinical and psychosocial dimensions of LVAD therapy
Advanced HFrEF carries high mortality, but LVAD therapy can improve survival, heart function, and quality of life.
-
Current standards in donor lung procurement and preservation
Review the American Association for Thoracic Surgery’s expert consensus guidelines for improving standardization in key areas of lung acquisition.
-
Looking ahead to CHEST 2025 in Chicago
CHEST President John Howington, MD, MBA, FCCP, hopes you will join him at CHEST 2025 as we come together to hear the latest advancements in the field and celebrate the remarkable milestone of 90 years of CHEST.
-
Top reads from the CHEST journal portfolio – September 2025
Editorial Board members share their insights on the association between mucus plugs and exacerbations, abnormal pediatric airways, and the association of central nervous system-related biomarkers with delirium.
-
Tezepelumab found to reduce oral corticosteroid use in severe asthma
The WAYFINDER study shows a clinically meaningful reduction in oral corticosteroid dosing, which may allow patients to get off steroids, said pulmonology expert Stephen T. Doyle, DO, MBA, FCCP.
